CompletedPhase 2NCT00033540
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
Studying Adenocarcinoma of the gallbladder and extrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Syma Iqbal, MDUniversity of Southern California
- Intervention
- capecitabine(drug)
- Enrollment
- 57 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2003 – 2011
Study locations (30)
- Mobile Infirmary Medical Center, Mobile, Alabama, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
- North Bay Cancer Center, Fairfield, California, United States
- Marin Cancer Institute at Marin General Hospital, Greenbrae, California, United States
- Sutter Health Western Division Cancer Research Group, Greenbrae, California, United States
- USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center, Orange, California, United States
- University of Colorado Cancer Center at University of Colorado Health Sciences Center, Aurora, Colorado, United States
- Memorial Hospital Cancer Center, Colorado Springs, Colorado, United States
- West Florida Regional Medical Center, Pensacola, Florida, United States
- Hematology Oncology Associates of Eastern Idaho, Idaho Falls, Idaho, United States
- Saint Anthony's Hospital at Saint Anthony's Health Center, Alton, Illinois, United States
- Cancer Care Center at St. Francis Hospital, Indianapolis, Indiana, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00033540 on ClinicalTrials.govOther trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07265674A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract CancerJ-Pharma Co., Ltd.
- RECRUITINGPHASE3NCT06282575Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerJazz Pharmaceuticals
- RECRUITINGNCT07007832Bile Omics for Diagnosing Indeterminate Biliary StricturesShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGPHASE1NCT03257761Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder CancerUniversity of Southern California
See all trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract →